Matches in Wikidata for { <http://www.wikidata.org/entity/Q102066604> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q102066604 description "2020 ވަނަ އަހަރުގެ އޮކްޓޯބަރުމަހުގެ 19ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ލިޔުމެއް" @default.
- Q102066604 description "article scientifique publié en 2020" @default.
- Q102066604 description "artículu científicu espublizáu n'ochobre de 2020" @default.
- Q102066604 description "scientific article published on 19 October 2020" @default.
- Q102066604 description "wetenschappelijk artikel" @default.
- Q102066604 description "наукова стаття, опублікована 19 жовтня 2020" @default.
- Q102066604 name "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 name "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 name "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 type Item @default.
- Q102066604 label "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 label "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 label "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 prefLabel "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 prefLabel "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 prefLabel "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 P1433 Q102066604-0F14E48A-F317-40BA-BE54-6EABAD9BFFBC @default.
- Q102066604 P1476 Q102066604-19AC91F2-3FDF-41A5-AD85-7DD23AFD2994 @default.
- Q102066604 P2093 Q102066604-1B610720-4B38-4843-BFE9-AEC933EE9622 @default.
- Q102066604 P2093 Q102066604-A3AC76AE-2625-445A-8B45-EBB41E34235C @default.
- Q102066604 P2093 Q102066604-A687C9F8-61A2-47BE-9475-52BD1D4A00B7 @default.
- Q102066604 P2093 Q102066604-B945E27D-0E11-4AFF-8386-5DBE9F66C3D5 @default.
- Q102066604 P2093 Q102066604-EE053721-167D-4A7C-A6DA-78C9DCEB0C68 @default.
- Q102066604 P2093 Q102066604-F01D812D-08DA-40F8-9ECC-131894EE77D7 @default.
- Q102066604 P2093 Q102066604-F1798674-1A7A-46FD-9E4E-D51FECFA2CE6 @default.
- Q102066604 P275 Q102066604-af1e6b38-e343-4b6d-96b8-843ded58f8a4 @default.
- Q102066604 P2860 Q102066604-657DCDFC-126F-4A06-97D2-895E42D7686D @default.
- Q102066604 P304 Q102066604-0267D51D-5678-40DF-B598-CF35D63D8B3A @default.
- Q102066604 P31 Q102066604-37857FCD-401C-443B-A9AB-8BA721938C22 @default.
- Q102066604 P356 Q102066604-EB433256-4273-41B8-821C-DBBBE7857516 @default.
- Q102066604 P478 Q102066604-6F505DD1-42C7-4124-9825-B1C5DDA1E774 @default.
- Q102066604 P577 Q102066604-2C6E4304-85DB-4F52-9E0F-FEB266F1BD46 @default.
- Q102066604 P6216 Q102066604-71ab6c74-7def-4075-902c-f08d2d7747e1 @default.
- Q102066604 P698 Q102066604-78E5E44E-1D7F-499C-B7EF-965CF224BA1F @default.
- Q102066604 P356 FIMMU.2020.595289 @default.
- Q102066604 P698 33193448 @default.
- Q102066604 P1433 Q27723748 @default.
- Q102066604 P1476 "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response" @default.
- Q102066604 P2093 "Andre De Souza" @default.
- Q102066604 P2093 "Benedito A Carneiro" @default.
- Q102066604 P2093 "Devalingam Mahalingam" @default.
- Q102066604 P2093 "Fabio A Tavora" @default.
- Q102066604 P2093 "Howard P Safran" @default.
- Q102066604 P2093 "Pamela N Munster" @default.
- Q102066604 P2093 "Wafik S El-Deiry" @default.
- Q102066604 P275 Q20007257 @default.
- Q102066604 P2860 Q80035792 @default.
- Q102066604 P304 "595289" @default.
- Q102066604 P31 Q13442814 @default.
- Q102066604 P356 "10.3389/FIMMU.2020.595289" @default.
- Q102066604 P478 "11" @default.
- Q102066604 P577 "2020-10-19T00:00:00Z" @default.
- Q102066604 P6216 Q50423863 @default.
- Q102066604 P698 "33193448" @default.